Join the PharmaShots Family of 20000+ Subscribers by PharmaShots

PharmaShots Dec 2, 2025

Roche’s Point-of-Care PCR Test Gains FDA’s 510(k) Clearance with CLIA Waiver and European CE Mark to Diagnose Bordetella infections

Shots: Ref: Roche | Image: Roche | Press Release Related News: Genentech (Roche) Reports Interim P-III (lidERA Breast…

Read article →
PharmaShots Dec 2, 2025

Belite Bio Reports Topline P-III (DRAGON) Trial Data on Tinlarebant for Stargardt Disease Type 1 (STGD1)

Shots: Ref: Belite Bio | Image: Belite Bio | Press Release Related News: Belite Bio Reports the MHRA’s CMA Application…

Read article →
PharmaShots Dec 2, 2025

Reuters Events | Pharma USA 2026 | 16-17 March | Philadelphia, USA

Healthcare is changing faster than we can react Companies have had to make billion-dollar bets on AI, manufacturing,…

Read article →
PharmaShots Dec 2, 2025

Accord Healthcare Launches Osvyrti and Jubereq (Biosimilar, Prolia & Xgeva) in the EU

Shots: Ref: PRNewswire | Image: Accord Healthcare | Press Release Related News: Accord Healthcare Reports the MHRA’s…

Read article →
PharmaShots Dec 2, 2025

Johnson & Johnson Reports the EC Approval of Imaavy (Nipocalimab) for Generalized Myasthenia Gravis (gMG)

Shots: Ref: GlobeNewswire | Image: Johnson & Johnson | Press Release Related News: Johnson & Johnson’s Tremfya…

Read article →
PharmaShots Dec 2, 2025

Regeneron and Tessera Therapeutics Enter ~$275M Collaboration to Advance TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD)

Shots: Ref: Regeneron | Image: Regeneron and Tessera Therapeutics | Press Release Related News: Regeneron and Sanofi…

Read article →
PharmaShots Dec 2, 2025

Akebia Therapeutics Acquires Q32 Bio’s Complement Inhibitor ADX-097 for ~$592M

Shots: Ref: Q32 Bio | Image: Akebia Therapeutics and Q32 Bio | Press Release Related News: Akebia’s Vafseo…

Read article →
PharmaShots Dec 1, 2025

Inside Sapient’s Multi-Omics Revolution: A Deep Dive with Founder Mo Jain 

Shots: Saurabh: How does Sapient’s collaboration with Alamar Biosciences improve Sapient’s multi-omics offerings, and…

Read article →